Literature DB >> 27335156

From Clozapine to Cognitive Remediation.

Jason Quinn1, Nathan J Kolla2,3,4.   

Abstract

OBJECTIVE: Although a minority of persons with schizophrenia (SCZ) commits violent acts, SCZ remains a risk factor for violence. Here, we present a broad overview of evidence-based treatments for violence in SCZ, including biological and psychosocial interventions.
METHOD: We conducted MEDLINE and PsychINFO literature searches to retrieve articles relating to treatments for violent, hostile, or aggressive behaviours in SCZ.
RESULTS: Clozapine shows the strongest evidence for treating the acute violence of SCZ. Other atypical antipsychotics also possess antiaggressive effects, although the evidence is not as robust as that for clozapine. Psychosocial treatments can be useful adjuncts to pharmacotherapy once patients' positive symptoms have stabilized. Cognitive behavioural therapy for psychosis and cognitive remediation are 2 psychosocial interventions that have demonstrated positive outcomes for violence in SCZ. Most psychosocial studies that examined violence as an outcome were conducted in forensic psychiatric settings.
CONCLUSIONS: Effective treatments exist for persons with SCZ who pose a risk for violent and aggressive behaviour, although the overall evidence base remains relatively weak. More randomized controlled trials of programs showing evidence for reduction of violence in SCZ are required. Further research should delineate which patients could benefit from multimodal treatment and where and when such treatments are optimally delivered.

Entities:  

Keywords:  aggression; schizophrenia; treatment; violence

Mesh:

Substances:

Year:  2016        PMID: 27335156      PMCID: PMC5298523          DOI: 10.1177/0706743716656830

Source DB:  PubMed          Journal:  Can J Psychiatry        ISSN: 0706-7437            Impact factor:   4.356


  69 in total

Review 1.  Treating comorbid substance use disorders in schizophrenia.

Authors:  Dan I Lubman; Joel A King; David J Castle
Journal:  Int Rev Psychiatry       Date:  2010

2.  Cognitive-behavioural therapy v. social activity therapy for people with psychosis and a history of violence: randomised controlled trial.

Authors:  Gillian Haddock; Christine Barrowclough; Jennifer J Shaw; Graham Dunn; Raymond W Novaco; Nicholas Tarrier
Journal:  Br J Psychiatry       Date:  2009-02       Impact factor: 9.319

Review 3.  Impulsivity and aggression in schizophrenia: a neural circuitry perspective with implications for treatment.

Authors:  Matthew J Hoptman
Journal:  CNS Spectr       Date:  2015-04-22       Impact factor: 3.790

4.  Revisiting the therapeutic effect of rTMS on negative symptoms in schizophrenia: a meta-analysis.

Authors:  Chuan Shi; Xin Yu; Eric F C Cheung; David H K Shum; Raymond C K Chan
Journal:  Psychiatry Res       Date:  2013-12-21       Impact factor: 3.222

5.  Violent behavior in mental illness: the role of substance abuse.

Authors:  Jan Volavka; Jeffrey Swanson
Journal:  JAMA       Date:  2010-08-04       Impact factor: 56.272

6.  Animal-assisted therapy and agitation and depression in nursing home residents with dementia: a matched case-control trial.

Authors:  Tomislav Majić; Hans Gutzmann; Andreas Heinz; Undine E Lang; Michael A Rapp
Journal:  Am J Geriatr Psychiatry       Date:  2013-07-03       Impact factor: 4.105

7.  Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST).

Authors:  Jan Volavka; Pal Czobor; Eske M Derks; Istvan Bitter; Jan Libiger; René S Kahn; W Wolfgang Fleischhacker
Journal:  J Clin Psychiatry       Date:  2011-07       Impact factor: 4.384

8.  Psychotic disorders and sex offending in a Danish birth cohort.

Authors:  Amanda Alden; Patricia Brennan; Sheilagh Hodgins; Sarnoff Mednick
Journal:  Arch Gen Psychiatry       Date:  2007-11

9.  Crime victimization in adults with severe mental illness: comparison with the National Crime Victimization Survey.

Authors:  Linda A Teplin; Gary M McClelland; Karen M Abram; Dana A Weiner
Journal:  Arch Gen Psychiatry       Date:  2005-08

10.  Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol.

Authors:  Jan Volavka; Pal Czobor; Karen Nolan; Brian Sheitman; Jean-Pierre Lindenmayer; Leslie Citrome; Joseph P McEvoy; Thomas B Cooper; Jeffrey A Lieberman
Journal:  J Clin Psychopharmacol       Date:  2004-04       Impact factor: 3.153

View more
  5 in total

1.  The Use of Scientific Evidence about Schizophrenia and Violence in Clinical Services.

Authors:  Rüdiger Müller-Isberner
Journal:  Can J Psychiatry       Date:  2017-02       Impact factor: 4.356

2.  Aggression, Alexithymia and Sense of Coherence in a Sample of Schizophrenic Outpatients.

Authors:  Argyro Pachi; Athanasios Tselebis; Ioannis Ilias; Effrosyni Tsomaka; Styliani Maria Papageorgiou; Spyros Baras; Evgenia Kavouria; Konstantinos Giotakis
Journal:  Healthcare (Basel)       Date:  2022-06-10

3.  Prescribing Patterns of Psychotropic Drugs and Risk of Violent Behavior: A Prospective, Multicenter Study in Italy.

Authors:  E di Giacomo; A Stefana; V Candini; G Bianconi; L Canal; M Clerici; G Conte; M T Ferla; L Iozzino; G Sbravati; G Tura; R Micciolo; G de Girolamo
Journal:  Int J Neuropsychopharmacol       Date:  2020-05-27       Impact factor: 5.176

4.  The Link Between Cannabis Use and Violent Behavior in the Early Phase of Psychosis: The Potential Role of Impulsivity.

Authors:  Valerie Moulin; David Framorando; Jacques Gasser; Elise Dan-Glauser
Journal:  Front Psychiatry       Date:  2022-03-22       Impact factor: 4.157

5.  A Systematic Review of Non-pharmacological Strategies to Reduce the Risk of Violence in Patients With Schizophrenia Spectrum Disorders in Forensic Settings.

Authors:  Rudolf Slamanig; Andreas Reisegger; Hildegard Winkler; Giovanni de Girolamo; Giuseppe Carrà; Cristina Crocamo; Heiner Fangerau; Inga Markiewicz; Janusz Heitzman; Hans Joachim Salize; Marco Picchioni; Johannes Wancata
Journal:  Front Psychiatry       Date:  2021-05-10       Impact factor: 4.157

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.